Co-endemicity of Opisthorchis viverrini and Strongyloides stercoralis infections: evidence from stool examination and serology screening in Champasak Province, Southern Lao People’s Democratic Republic
摘要
Helminth infections remain a major public health problem in the Lao People’s Democratic Republic (Lao PDR), particularly in rural communities where foodborne trematodes and soil-transmitted helminths are co-endemic. Opisthorchis viverrini is a well-established risk factor for cholangiocarcinoma, while Strongyloides stercoralis can cause severe and potentially fatal disease. This study aimed to determine the prevalence and patterns of helminth infections in southern Lao PDR using combined parasitological and serological diagnostic approaches. A community-based cross-sectional study was conducted among 242 adults residing in three rural villages in Champasak Province, southern Lao PDR. Stool samples were examined using the formalin–ethyl acetate concentration technique (FECT), and point-of-care immunochromatographic tests (ICTs) were applied to detect IgG antibodies against O. viverrini and S. stercoralis. Overall, 69.0% of participants were infected with at least one helminth species. O. viverrini was the most prevalent parasite, detected in 51.7% by FECT and 65.3% by ICT. Other common infections included minute intestinal flukes (20.2%), hookworms (14.9%), S. stercoralis (9.9% by FECT; 14.5% by ICT), Trichostrongylus spp. (9.1%), and Taenia spp. (6.2%). Polyparasitism was frequent, with 9.1% harboring three or more helminth species. The estimated true prevalences, based on combined results from stool examination and serological testing, were 66.6% for opisthorchiasis and 13.5% for strongyloidiasis. ICT identified substantially more infections than stool examination alone for both O. viverrini and S. stercoralis. Serological ICT screening offers a sensitive, practical complement to parasitological methods. Integrated diagnostics are essential for improved surveillance and targeted interventions in resource-limited endemic areas. Clinical trial number: not applicable.